Acumen Pharmaceuticals, Inc. (ABOS)
Automate Your Wheel Strategy on ABOS
With Tiblio's Option Bot, you can configure your own wheel strategy including ABOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABOS
- Rev/Share 0.0
- Book/Share 2.5695
- PB 0.5449
- Debt/Equity 0.1865
- CurrentRatio 8.0221
- ROIC -0.6835
- MktCap 84802760.0
- FreeCF/Share -1.6945
- PFCF -0.8269
- PE -0.7289
- Debt/Assets 0.1418
- DivYield 0
- ROE -0.5824
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABOS | Citigroup | -- | Buy | -- | $4 | June 17, 2025 |
News
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
Read More
About Acumen Pharmaceuticals, Inc. (ABOS)
- IPO Date 2021-07-01
- Website https://acumenpharm.com
- Industry Biotechnology
- CEO Daniel J. O'Connell
- Employees 61